Tiziana Receives $3.4 Million in Non-Dilutive Funding

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here. About Foralumab About Tiziana Life Sciences For further inquiries: [1] https://www.pnas.org/doi/10.1073/pnas.2220272120 Gabriele Cerro ...